Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

ANBL0321: CT/MRI Response Assessment Form NCT00053326

- 03.07.15 - 1 modulo, 4 itemgroups, 18 elementi, 1 linguaggio

Itemgroups: Header, CT/MRI Response Assessment, New Lesion, CCRR MODULE

ANBL0321: CT/MRI Response Assessment Form NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968DB9B-1F21-22F4-E034-0003BA12F5E7

Neuroblastoma NCT00053326 Pre-Study - ANBL0321: CT/MRI Sites of Disease at study entry - 2089140v3.0 - ANBL0321: CT/MRI Sites of Disease at study entry

- 09.01.15 - 1 modulo, 3 itemgroups, 19 elementi, 1 linguaggio

Itemgroups: Header, Sites of Measurable Disease at the Time of Study Entry, CCRR MODULE

ANBL0321: CT/MRI Sites of Disease at study entry Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B966743D-6A11-0A66-E034-0003BA12F5E7

dbGaP phs000868 Transcriptome Sequencing of Pediatric Neuroblastoma - Eligibility

- 16.03.24 - 5 moduli, 1 ItemGroup, 1 elemento, 1 linguaggio

ItemGroup: IG.elig

Principal Investigator: Javed Khan, National Institutes of Health, Bethesda, MD, USA MeSH: Neuroblastoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000868 Neuroblastoma is the most common extra-cranial solid tumor in children. It represents 8% to 10% of all childhood cancers. Stage 4 Neuroblastoma is characterized by its clinical heterogeneous outcome. The special category, stage 4S tumors (2-5% of all NB) are chemo-sensitive, and the patients show spontaneous regression. On the other hand, MYCN amplification (25-30% of all NB) is associated with poor outcome of neuroblastoma, thus we further categorize stage 4 neuroblastoma into MYCN non-amplified and MYCN amplified group. Here we use transcriptome sequencing to characterize the transcriptome in 29 stage 4 Neuroblastoma samples.

Neuroblastoma

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 20.09.21 - 16 moduli, 16 itemgroups, 68 elementi, 1 linguaggio

Itemgroups: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module

NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln